Diseases and Conditions

The nonclinical drug candidates that Akros Pharma takes into clinical development come out of the research conducted by the Central Pharmaceutical Research Institute (CPRI) of JT Pharmaceuticals in Osaka, Japan. The current development focus for Akros reflects the research focus at CPRI.

Currently, CPRI and Akros are working to develop new therapeutics for the following disease states:

Code (Generic Name)

Potential Indication

Dosage form



  • Autoimmune diseases
  • Allergic diseases
OralInterleukin-2 inducible T cell kinase inhibitorSuppresses overactive immune response via inhibition of the signal to activate T cells related to immune response.Phase2
  • Type 2 diabetes mellitus
OralSGLT1 inhibitorSuppresses postprandial hyperglycemia and normalizes blood glucose level via inhibition of SGLT1.Phase1
  • Chronic heart failure
OralPDHK inhibitorImproves cardiac function by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism.Phase2
  • Neurodegenerative disease
OralPDHK inhibitorImproves metabolic abnormalities by activation of pyruvate dehydrogenase (PDH).Phase1
  • Pulmonary arterial hypertension
OralPim-1 inhibitorSuppresses pulmonary vascular cell proliferation by inhibiting Pim-1.Phase1
  • Autoinflammatory/
    Autoimmune diseases
OralNLRP3 inhibitorSuppresses immune response by inhibition of NLRP3 inflammasomePhase1

Clinical trial phase presented above is based on the first dose.